Alexander Sakers

Alexander Sakers

Auto-generated profile, based on publicly available information

Alexander Sakers

Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2019 in Science
Verified
Journal Article
Closed access
PDF file
DMDavid Merrick
David Merrick
ASAlexander Sakers
Alexander Sakers
ZIZhazira Irgebay
Zhazira Irgebay
COChihiro Okada
Chihiro Okada
CCCatherine Calvert
Catherine Calvert
PSPatrick Seale
Patrick Seale
A singular focus on fat: Fatty tissue can expand in two ways: through increases in the size of individual adipocytes or through increases in the number of adipocytes. The former process promotes metabolic disease, and the latter protects against it. Merrick et al. used single-cell RNA sequencing to define the hierarchy of mesenchymal progenitor cells that give rise to adipose tissue in mice and humans (see the Perspective by Chau and Cawthorn). They found that progenitor cells expressing a protein called DPP4 give rise to two distinct types of preadipocytes in response to different signals. The DPP4 progenitors reside in a fluid-filled network of collagen and elastin fibers surrounding adipose tissue. In principle, therapeutic interventions that increase progenitor cell differentiation into adipocytes could ameliorate metabolic disease. Science , this issue p. eaav2501 ; see also p. 328

1 July 2019 in Cell Metabolism
Verified
Journal Article
Closed access
WWWenshan Wang
Wenshan Wang
JIJeff Ishibashi
Jeff Ishibashi
STSophie Trefely
Sophie Trefely
MSMengle Shao
Mengle Shao
ACAlexis J. Cowan
Alexis J. Cowan
PSPatrick Seale
Patrick Seale

1 December 2019 in Cell Stem Cell
Verified
Journal Article
Closed access
RSRachel R. Stine
Rachel R. Stine
ASAlexander P. Sakers
Alexander P. Sakers
TTTara TeSlaa
Tara TeSlaa
MKMegan Kissig
Megan Kissig
ZSZachary E. Stine
Zachary E. Stine
PSPatrick Seale
Patrick Seale

1 April 2017 in Genes & Development
Verified
Journal Article
Open access
PDF file
SSSuzanne N. Shapira
Suzanne N. Shapira
HLHee-Woong Lim
Hee-Woong Lim
SRSona Rajakumari
Sona Rajakumari
ASAlexander P. Sakers
Alexander P. Sakers
JIJeff Ishibashi
Jeff Ishibashi
PSPatrick Seale
Patrick Seale
The transcription factor early B-cell factor 2 (EBF2) is an essential mediator of brown adipocyte commitment and terminal differentiation. However, the mechanisms by which EBF2 regulates chromatin to activate brown fat-specific genes in adipocytes were unknown. ChIP-seq (chromatin immunoprecipitation [ChIP] followed by deep sequencing) analyses in brown adipose tissue showed that EBF2 binds and regulates the activity of lineage-specific enhancers. Mechanistically, EBF2 physically interacts with the chromatin remodeler BRG1 and the BAF chromatin remodeling complex in brown adipocytes. We identified the histone reader protein DPF3 as a brown fat-selective component of the BAF complex that was required for brown fat gene programming and mitochondrial function. Loss of DPF3 in brown adipocytes reduced chromatin accessibility at EBF2-bound enhancers and led to a decrease in basal and catecholamine-stimulated expression of brown fat-selective genes. Notably, Dpf3 is a direct transcriptional target of EBF2 in brown adipocytes, thereby establishing a regulatory module through which EBF2 activates and also recruits DPF3-anchored BAF complexes to chromatin. Together, these results reveal a novel mechanism by which EBF2 cooperates with a tissue-specific chromatin remodeling complex to activate brown fat identity genes.

9 February 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RMReed Mszar
Reed Mszar
SBSarah Bart
Sarah Bart
ASAlexander Sakers
Alexander Sakers
DSDaniel Soffer
Daniel Soffer
DKDean G. Karalis
Dean G. Karalis
Hypertriglyceridemia (HTG) is a prevalent medical condition in patients with cardiometabolic risk factors and is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), if left undiagnosed and undertreated. Current guidelines identify HTG as a risk-enhancing factor and, as a result, recommend clinical evaluation and lifestyle-based interventions to address potential secondary causes of elevated triglyceride (TG) levels. For individuals with mild to moderate HTG at risk of ASCVD, statin therapy alone or in combination with other lipid-lowering medications known to decrease ASCVD risk are guideline-endorsed. In addition to lifestyle modifications, patients with severe HTG at risk of acute pancreatitis may benefit from fibrates, mixed formulation omega-3 fatty acids, and niacin; however, evidence does not support their use for ASCVD risk reduction in the contemporary statin era. Novel therapeutics including those that target apoC-III and ANGPTL3 have shown to be safe, well-tolerated, and effective for lowering TG levels. Given the growing burden of cardiometabolic disease and risk factors, public health and health policy strategies are urgently needed to enhance access to effective pharmacotherapies, affordable and nutritious food options, and timely health care services.